Frost & Sullivan releases 'Research on the Chinese Innovative Diabetes Drug Market - GLP-1 Receptor Agonists in the Diabetes and Weight Management Sectors: Market and Development Prospects'

Based on research into the Chinese innovative diabetes drug market, Frost & Sullivan (Frost & Sullivan) has released a related industry report. The report indicates that the current structure of the Chinese diabetes drug market is still dominated by traditional diabetes medications. The penetration rate of new types of diabetes drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors is low, leaving significant room for market development. Moreover, the good weight loss effects of GLP-1 drugs also offer them tremendous potential in the weight management market.